Bodycote shareholders will vote next week on a board-backed 940p-per-share cash takeover by Veritas Capital that would end the heat-treatment group's London listing.
Bodycote (LSE:BOY), the heat-treatment and specialist thermal processing group, is approaching a decisive moment. Shareholders are due to vote on 21 October 2026 on the board-backed cash acquisition of the company by US private equity firm Veritas Capital at 940 pence per share. A court meeting is scheduled for 10.00am London time, followed by a general meeting at 10.15am.
A contested path to a deal
The process attracted more than one suitor. CVC Advisers confirmed in late September that it would not make an offer, leaving Veritas as the remaining bidder. Bodycote (LSE:BOY) has since remained in an offer period, with a steady flow of dealing disclosures and holdings notifications from institutional investors through mid-October.
Based on market data reported in early October, Bodycote shares closed at 910.5p on 2 October, a discount of roughly 3% to the offer price. That gap typically reflects the time remaining until completion and the risk that conditions are not met. The shares had traded as low as 585p over the previous 52 weeks and as high as 967.5p, and the group's market value was about £1.5bn.
If shareholders approve the scheme, it would still require court sanction and the satisfaction or waiver of other conditions. The transaction is expected to become effective in the first quarter of 2027, after which Bodycote's shares would be delisted and the company would leave the FTSE 250.
Operational picture
The offer arrives after a period of improving operational performance. For the six months to 30 June 2026, revenue rose 3% to £381.2m, while net income increased 12% to £31m. The Specialist Technologies business, which includes higher-value processes serving aerospace and other demanding end markets, grew revenue by 15% to £121.2m. Precision Heat Treatment, the larger but more cyclical division, grew 2% to £250.8m.
Management has been pursuing a streamlining programme designed to lift margins by consolidating its plant network, and alongside its 2025 results it launched an £80m share buyback. Aerospace momentum and self-help measures have been the main drivers of margin improvement, factors that will have formed part of the backdrop to the board's assessment of the bid.
What investors are watching
The key question now is whether the scheme secures the required majorities. At the court meeting, approval requires a majority in number of shareholders voting, representing at least 75% in value of the shares voted. The general meeting resolution needs at least 75% of votes cast. Holdings notifications filed in the days before the vote show that investors have continued to adjust their positions.
Should the deal be approved, attention will shift to the regulatory and court timetable leading to completion. If it were to fail, Bodycote would return to trading on its fundamentals, with investors focused on the pace of industrial recovery in Europe and North America, the contribution from Specialist Technologies and progress on cost savings.
For a company that has been a long-standing member of the UK mid-cap index, a successful vote would mark the start of the final chapter of its listed life. For now, the share price is likely to track the offer terms closely, with movements largely reflecting perceived deal certainty rather than trading news.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...